[On-Site] How Far Is Dementia Research Expanding?

While the first day of the forum focused on reviewing the clinical issues and conceptual framework surrounding Alzheimer's disease and related dementias, the second day covered a broad range of mechanisms and technologies in dementia research — from lysosomal pathology and biomarkers to digital and electronic therapeutics. It was a day that brought together basic researchers, clinicians, and the bio industry to survey the full landscape of dementia research. Day 2 of the 9th Neuroscience Forum for Alzheimer's Disease (NFAD) made clear that dementia research has entered a stage where no single technology or hypothesis can carry the field alone. Across five symposiums — spanning lysosomal pathology, blood biomarkers and proteomics, digital biomarkers, and electronic and physical therapeutic technologies — a total of 23 presentations were delivered in succession. Basic biology, clinical cohort research, and commercialization strategy converged in a single space, offering a shared view of where dementia research stands today and where it is headed next. NFAD is an academic forum that brings together clinicians, basic researchers, and industry professionals to examine the clinical significance of research findings on Alzheimer's disease, various forms of dementia, and neurodegenerative diseases. The second day's program clearly traced a progression from "deepening understanding of disease mechanisms" to "precision diagnostics," "digital transformation," and finally "therapeutic technologies." Hyundoo Hwang, CEO of BREDIS Healthcare, introduced NULISA-based ultrasensitive protein analysis technology. NULISA is an analytical platform designed to reliably measure proteins present in blood at extremely low concentrations, with the entire measurement process automated to improve the consistency of results. CEO Hwang explained that this technology can stably detect dementia-related proteins with very low blood concentrations — such as pTau, GFAP, and NfL — at a level of sensitivity far exceeding that of conventional methods. He noted that in long-term cohort studies, where the same individuals must be measured repeatedly over time, automation and high sensitivity are essential for clinical application, as they help minimize errors arising from differences between operators or variations in experimental conditions.